{"nctId":"NCT04414345","briefTitle":"HEALEY ALS Platform Trial - Regimen C CNM-Au8","startDateStruct":{"date":"2020-07-30","type":"ACTUAL"},"conditions":["Amyotrophic Lateral Sclerosis"],"count":161,"armGroups":[{"label":"CNM-Au8","type":"EXPERIMENTAL","interventionNames":["Drug: CNM-Au8"]},{"label":"Matching Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching Placebo"]}],"interventions":[{"name":"CNM-Au8","otherNames":[]},{"name":"Matching Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\nExclusion Criteria:\n\n* The following exclusion criterion is in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\n  1. History of allergy to gold, gold salts, or colloidal gold preparations.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease Progression as Assessed by the ALSFRS-R Total Score","description":"Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.01","spread":"0.075"},{"groupId":"OG001","value":"-1.03","spread":"0.072"}]}]}]},{"type":"PRIMARY","title":"Mortality Event Rate","description":"Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.006","spread":"0.002"},{"groupId":"OG001","value":"0.007","spread":"0.002"}]}]}]},{"type":"SECONDARY","title":"Respiratory Function","description":"Change in respiratory function as assessed by slow vital capacity (SVC).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.32","spread":"1.362"},{"groupId":"OG001","value":"-8.53","spread":"1.146"}]}]}]},{"type":"SECONDARY","title":"Muscle Strength","description":"Change in muscle strength as measured isometrically using hand-held dynamometry (HHD).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.54","spread":"2.647"},{"groupId":"OG001","value":"-24.44","spread":"2.260"}]}]}]},{"type":"SECONDARY","title":"Number of Participants That Experienced Death or Death Equivalent","description":"The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22hours per day for more than 7 days in a row.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":120},"commonTop":["Fall","Muscular weakness","Diarrhoea","Nausea","Fatigue"]}}}